newsfilter
← Latest News
GlobeNewswire·

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

  • RenovoRx, Inc. (NASDAQ: RNXT) was ranked number 10 in the medical device category on Fast Company's 2026 list of the World's Most Innovative Companies.
  • CEO Shaun Bagai stated the recognition reflects the company's commitment to transforming cancer patient lives through targeted delivery solutions for difficult-to-treat tumors like pancreatic cancer.
  • The company's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, enabled by the RenovoCath device, delivers therapeutics near tumor sites to potentially minimize toxicity versus systemic intravenous therapy.
  • RenovoCath generated approximately $1.1 million in sales during its first full year of commercial revenue in 2025, with growing adoption at high-volume U.S. cancer centers.
  • The company estimates an initial total addressable market of approximately $400 million for RenovoCath as a stand-alone device, with potential for multi-billion-dollar growth as the platform expands.
  • RenovoRx is evaluating its drug-device combination candidate IAG (intra-arterial gemcitabine) in the ongoing Phase III TIGeR-PaC trial, which has received Orphan Drug Designation for pancreatic & bile duct cancer.
  • Fast Company's 2026 Most Innovative Companies Summit & Gala for honorees will be held on May 19 in New York City.
  • RenovoRx continues to explore revenue-generating activities through its own efforts or in partnership with medical device commercial partners to meet anticipated demand.